Sunday, September 19, 2021 4:29:20 PM
Black-Ops,
I'm not necessarily seeing the shorts exiting at this time.
I was comparing the data around the short positions from late Jun 2020 and now (see sheet below). It really doesn't look like the shorts are exiting their long term short positions - in fact, I think it has become even more entrenched.
From Jun 2020 to now, the CYDY daily volume is lower, the number of shares being borrowed has doubled, the number of loans has ramped up (~100 vs ~200), and the cost to borrow is half (~20 vs ~10). The shares short utilization in Jun 20 was 60-70%....now it is basically 100%. The average age of contract has almost quadrupled (~13 to ~60).
To me it looks like there are more longer term short positions and it comes out to be on average a higher number of shares per contract (~150K).
Between 11Jul2021 and 20Jul2021 there was a significant number flurry of shares short contracted (from ~2M/day to 25M/day).
The "Security Lending Volume" (meaning contracted shares short) is about the daily short volume. So, it looks like some day traders jumping in/out, but the average age of the contracts has increased.
On the up side.....the days to cover is 10x from Jun 2020, and the contract age is 4x. There are some serious holdout bears hanging in there.
I sense another significant bear raid getting ready in the next couple of weeks if there is no concrete news that gets announced. If there is good news then we can expect some pain inflicted on the shorts...otherwise.....the roller coaster continues.
ps. Data pulled from https://www.ortex.com/symbol/OTCPK/CYDY/short_interest
I'm not necessarily seeing the shorts exiting at this time.
I was comparing the data around the short positions from late Jun 2020 and now (see sheet below). It really doesn't look like the shorts are exiting their long term short positions - in fact, I think it has become even more entrenched.
From Jun 2020 to now, the CYDY daily volume is lower, the number of shares being borrowed has doubled, the number of loans has ramped up (~100 vs ~200), and the cost to borrow is half (~20 vs ~10). The shares short utilization in Jun 20 was 60-70%....now it is basically 100%. The average age of contract has almost quadrupled (~13 to ~60).
To me it looks like there are more longer term short positions and it comes out to be on average a higher number of shares per contract (~150K).
Between 11Jul2021 and 20Jul2021 there was a significant number flurry of shares short contracted (from ~2M/day to 25M/day).
The "Security Lending Volume" (meaning contracted shares short) is about the daily short volume. So, it looks like some day traders jumping in/out, but the average age of the contracts has increased.
On the up side.....the days to cover is 10x from Jun 2020, and the contract age is 4x. There are some serious holdout bears hanging in there.
I sense another significant bear raid getting ready in the next couple of weeks if there is no concrete news that gets announced. If there is good news then we can expect some pain inflicted on the shorts...otherwise.....the roller coaster continues.
ps. Data pulled from https://www.ortex.com/symbol/OTCPK/CYDY/short_interest
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM

